

# Scott V Bratman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1729923/publications.pdf>

Version: 2024-02-01

133  
papers

10,949  
citations

81889

39  
h-index

33889

99  
g-index

144  
all docs

144  
docs citations

144  
times ranked

18579  
citing authors

#	ARTICLE	IF	CITATIONS
1	The prognostic landscape of genes and infiltrating immune cells across human cancers. <i>Nature Medicine</i> , 2015, 21, 938-945.	30.7	2,505
2	An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. <i>Nature Medicine</i> , 2014, 20, 548-554.	30.7	1,771
3	Integrated digital error suppression for improved detection of circulating tumor DNA. <i>Nature Biotechnology</i> , 2016, 34, 547-555.	17.5	837
4	Sensitive tumour detection and classification using plasma cell-free DNA methylomes. <i>Nature</i> , 2018, 563, 579-583.	27.8	624
5	Prediction of acute myeloid leukaemia risk in healthy individuals. <i>Nature</i> , 2018, 559, 400-404.	27.8	617
6	Refining American Joint Committee on Cancer/Union for International Cancer Control TNM Stage and Prognostic Groups for Human Papillomavirus-Related Oropharyngeal Carcinomas. <i>Journal of Clinical Oncology</i> , 2015, 33, 836-845.	1.6	345
7	Circulating tumor DNA and liquid biopsy in oncology. <i>Nature Cancer</i> , 2020, 1, 276-290.	13.2	309
8	Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. <i>Nature Cancer</i> , 2020, 1, 873-881.	13.2	253
9	FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution. <i>Bioinformatics</i> , 2014, 30, 3390-3393.	4.1	212
10	Metabolic regulation of dermal fibroblasts contributes to skin extracellular matrix homeostasis and fibrosis. <i>Nature Metabolism</i> , 2019, 1, 147-157.	11.9	150
11	Bioactive DNA from extracellular vesicles and particles. <i>Cell Death and Disease</i> , 2020, 11, 584.	6.3	125
12	Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA. <i>Nature Protocols</i> , 2019, 14, 2749-2780.	12.0	118
13	Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. <i>Lancet Oncology</i> , The, 2018, 19, e240-e251.	10.7	108
14	Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates. <i>Nature Communications</i> , 2017, 8, 15086.	12.8	107
15	Senescence, Necrosis, and Apoptosis Govern Circulating Cell-free DNA Release Kinetics. <i>Cell Reports</i> , 2020, 31, 107830.	6.4	100
16	Osteoradionecrosis of the mandible in patients with oropharyngeal carcinoma treated with intensity-modulated radiotherapy. <i>Cancer</i> , 2017, 123, 3691-3700.	4.1	99
17	Long-Term Late Toxicity, Quality of Life, and Emotional Distress in Patients With Nasopharyngeal Carcinoma Treated With Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 340-352.	0.8	99
18	Human Papillomavirus Genotype Association With Survival in Head and Neck Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2016, 2, 823.	7.1	98

#	ARTICLE	IF	CITATIONS
19	Current State of PCR-Based Epstein-Barr Virus DNA Testing for Nasopharyngeal Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	85
20	Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROC. <i>Blood</i> , 2019, 133, 237-245.	1.4	85
21	SUNSET: Stereotactic Radiation for Ultracentral Non-“Small-Cell Lung Cancer”-Safety and Efficacy Trial. <i>Clinical Lung Cancer</i> , 2018, 19, e529-e532.	2.6	84
22	Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 715-719.	3.1	75
23	Clinical Utility of Epstein-Barr Virus DNA Testing in the Treatment of Nasopharyngeal Carcinoma Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 996-1001.	0.8	73
24	Plasma redox imbalance caused by albumin oxidation promotes lung-predominant NETosis and pulmonary cancer metastasis. <i>Nature Communications</i> , 2018, 9, 5116.	12.8	72
25	Galectin-1 Mediates Radiation-Related Lymphopenia and Attenuates NSCLC Radiation Response. <i>Clinical Cancer Research</i> , 2014, 20, 5558-5569.	7.0	64
26	Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non-“Small Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv211.	6.3	64
27	Body mass index and prognosis in patients with head and neck cancer. <i>Head and Neck</i> , 2017, 39, 1226-1233.	2.0	64
28	Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. <i>Nature Communications</i> , 2021, 12, 5137.	12.8	63
29	Re-evaluation of Ipsilateral Radiation for T1-T2N0-N2b Tonsil Carcinoma at the Princess Margaret Hospital in the Human Papillomavirus Era, 25 Years Later. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 159-169.	0.8	61
30	Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challenges. <i>Science Advances</i> , 2022, 8, eabi8618.	10.3	61
31	Radiomic Biomarkers to Refine Risk Models for Distant Metastasis in HPV-related Oropharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1107-1116.	0.8	57
32	Outcomes and prognostic factors for major salivary gland carcinoma following postoperative radiotherapy. <i>Oral Oncology</i> , 2016, 54, 75-80.	1.5	56
33	Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma. <i>Cell Reports</i> , 2018, 25, 1318-1331.e4.	6.4	56
34	Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 4230-4244.	7.0	53
35	Radiologic Extranodal Extension Portends Worse Outcome in cN+ TNM-8 Stage I Human Papillomavirus-Mediated Oropharyngeal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 1017-1027.	0.8	50
36	Radiologic-Pathologic Correlation of Extranodal Extension in Patients With Squamous Cell Carcinoma of the Oral Cavity: Implications for Future Editions of the TNM Classification. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 698-708.	0.8	48

#	ARTICLE	IF	CITATIONS
37	Privacy-preserving distributed learning of radiomics to predict overall survival and HPV status in head and neck cancer. <i>Scientific Reports</i> , 2020, 10, 4542.	3.3	46
38	Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal. <i>Cancer</i> , 2020, 126, 3426-3437.	4.1	42
39	Radiologic-Pathologic Correlation of Tumor Thickness and Its Prognostic Importance in Squamous Cell Carcinoma of the Oral Cavity: Implications for the Eighth Edition Tumor, Node, Metastasis Classification. <i>American Journal of Neuroradiology</i> , 2018, 39, 1896-1902.	2.4	40
40	Cell-Free DNA Kinetics in a Pre-Clinical Model of Head and Neck Cancer. <i>Scientific Reports</i> , 2017, 7, 16723.	3.3	39
41	Predictors of Early Recurrence Prior to Planned Postoperative Radiation Therapy for Oral Cavity Squamous Cell Carcinoma and Outcomes Following Salvage Intensified Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 363-373.	0.8	38
42	A cross sectional study in cognitive and neurobehavioral impairment in long-term nasopharyngeal cancer survivors treated with intensity-modulated radiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 131, 179-185.	0.6	38
43	HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA. <i>Clinical Cancer Research</i> , 2021, 27, 5857-5868.	7.0	38
44	Morphologic and topographic radiologic features of human papillomavirus-related and "unrelated" oropharyngeal carcinoma. <i>Head and Neck</i> , 2017, 39, 1524-1534.	2.0	37
45	High efficiency error suppression for accurate detection of low-frequency variants. <i>Nucleic Acids Research</i> , 2019, 47, e87-e87.	14.5	36
46	The impact of the variation of imaging parameters on the robustness of Computed Tomography radiomic features: A review. <i>Computers in Biology and Medicine</i> , 2021, 133, 104400.	7.0	36
47	Lymph node ratio relationship to regional failure and distant metastases in oral cavity cancer. <i>Radiotherapy and Oncology</i> , 2017, 124, 225-231.	0.6	33
48	Prognostic importance of radiologic extranodal extension in HPV-positive oropharyngeal carcinoma and its potential role in refining TNM-8 cN-classification. <i>Radiotherapy and Oncology</i> , 2020, 144, 13-22.	0.6	30
49	Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck. <i>Cancer Treatment Reviews</i> , 2017, 54, 43-57.	7.7	28
50	Functional significance of U2AF1 S34F mutations in lung adenocarcinomas. <i>Nature Communications</i> , 2019, 10, 5712.	12.8	27
51	Circulating Human Papillomavirus DNA as a Biomarker of Response in Patients With Locally Advanced Cervical Cancer Treated With Definitive Chemoradiation. <i>JCO Precision Oncology</i> , 2018, 2, 1-8.	3.0	26
52	Human papillomavirus and p16 immunostaining, prevalence and prognosis of squamous carcinoma of unknown primary in the head and neck region. <i>International Journal of Cancer</i> , 2019, 145, 1465-1474.	5.1	24
53	Designing circulating tumor DNA-based interventional clinical trials in oncology. <i>Genome Medicine</i> , 2019, 11, 22.	8.2	24
54	Modeling Cellular Response in Large-Scale Radiogenomic Databases to Advance Precision Radiotherapy. <i>Cancer Research</i> , 2019, 79, 6227-6237.	0.9	23

#	ARTICLE	IF	CITATIONS
55	Non-operative management for oral cavity carcinoma: Definitive radiation therapy as a potential alternative treatment approach. <i>Radiotherapy and Oncology</i> , 2021, 154, 70-75.	0.6	23
56	Prognostic importance of radiologic extranodal extension in nasopharyngeal carcinoma treated in a Canadian cohort. <i>Radiotherapy and Oncology</i> , 2021, 165, 94-102.	0.6	22
57	Emerging technologies and their impact on regulatory science. <i>Experimental Biology and Medicine</i> , 2022, 247, 1-75.	2.4	22
58	Evolving trends in the initial locoregional management of male breast cancer. <i>Breast</i> , 2012, 21, 296-302.	2.2	21
59	Radiotherapy Characteristics and Outcomes for Head and Neck Carcinoma of Unknown Primary vs T1 Base-of-Tongue Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016, 142, 1208.	2.2	20
60	Cell-free DNA as a post-treatment surveillance strategy: current status. <i>Seminars in Oncology</i> , 2017, 44, 330-346.	2.2	20
61	Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study. , 2021, 9, e003476.		20
62	Exploring the Impact of Human Papillomavirus Status, Comorbidity, Polypharmacy, and Treatment Intensity on Outcome of Elderly Oropharyngeal Cancer Patients Treated With Radiation Therapy With or Without Chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 858-867.	0.8	19
63	Distant Metastases Following Postoperative Intensity-Modulated Radiotherapy for Oral Cavity Squamous Cell Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 368.	2.2	19
64	Utilizing circulating tumour DNA in radiation oncology. <i>Radiotherapy and Oncology</i> , 2017, 124, 357-364.	0.6	19
65	Non-invasive imaging prediction of tumor hypoxia: A novel developed and externally validated CT and FDG-PET-based radiomic signatures. <i>Radiotherapy and Oncology</i> , 2020, 153, 97-105.	0.6	19
66	Transitions in oral and gut microbiome of HPV+ oropharyngeal squamous cell carcinoma following definitive chemoradiotherapy (ROMA LA-OPSCC study). <i>British Journal of Cancer</i> , 2021, 124, 1543-1551.	6.4	19
67	Partial Laryngeal IMRT for T2NO Glottic Cancer: Impact of Image Guidance and Radiation Therapy Intensification. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 941-949.	0.8	17
68	Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 522-529.	0.8	16
69	Rationale and Protocol for a Canadian Multicenter Phase II Randomized Trial Assessing Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-â€œsmall-cell Lung Cancer (NCT02788461). <i>Clinical Lung Cancer</i> , 2018, 19, e699-e703.	2.6	15
70	Toronto Workshop on Late Recurrence in Estrogen Receptor-â€œPositive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz050.	2.9	15
71	The Prevalence and Determinants of Return to Work in Nasopharyngeal Carcinoma Survivors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 134-145.	0.8	15
72	Impact of cisplatin dose and smoking pack-years in human papillomavirus-â€œpositive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. <i>European Journal of Cancer</i> , 2019, 118, 112-120.	2.8	14

#	ARTICLE	IF	CITATIONS
73	Computer-assisted image analysis of the tumor microenvironment on an oral tongue squamous cell carcinoma tissue microarray. <i>Clinical and Translational Radiation Oncology</i> , 2019, 17, 32-39.	1.7	14
74	The Utility of Liquid Biopsies in Radiation Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 873-886.	0.8	14
75	Genomic biomarkers for precision radiation medicine. <i>Lancet Oncology</i> , The, 2017, 18, e238.	10.7	12
76	Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML. <i>Blood Advances</i> , 2019, 3, 2307-2311.	5.2	12
77	Solid Malignancies in Individuals With Down Syndrome: A Case Presentation and Literature Review. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1537-1545.	4.9	11
78	Impact of Type 2 Diabetes Mellitus on Survival in Head and Neck Squamous Cell Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2017, 157, 657-663.	1.9	11
79	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkr049.	2.9	11
80	Postoperative wound infections, neutrophil-to-lymphocyte ratio, and cancer recurrence in patients with oral cavity cancer undergoing surgical resection. <i>Oral Oncology</i> , 2019, 97, 23-30.	1.5	11
81	Impact of metformin on disease control and survival in patients with head and neck cancer: a retrospective cohort study. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2019, 48, 34.	1.9	11
82	Inflammatory Biomarkers, Hematopoietic Stem Cells, and Symptoms in Breast Cancer Patients Undergoing Adjuvant Radiation Therapy. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa037.	2.9	11
83	Prognostic value of clinical and radiologic extranodal extension and their role in the 8th edition TNM cN classification for HPV-negative oropharyngeal carcinoma. <i>Oral Oncology</i> , 2021, 114, 105167.	1.5	11
84	Prediction of Human Papillomavirus (HPV) Association of Oropharyngeal Cancer (OPC) Using Radiomics: The Impact of the Variation of CT Scanner. <i>Cancers</i> , 2021, 13, 2269.	3.7	10
85	Cell-free DNA and circulating tumor cell kinetics in a pre-clinical head and neck Cancer model undergoing radiation therapy. <i>BMC Cancer</i> , 2021, 21, 1075.	2.6	10
86	Clinical presentation and outcome of human papillomavirus-positive nasopharyngeal carcinoma in a North American cohort. <i>Cancer</i> , 2022, 128, 2908-2921.	4.1	10
87	The Cisplatin Total Dose and Concomitant Radiation in Locoregionally Advanced Head and Neck Cancer: Any Recent Evidence for Dose Efficacy?. <i>Current Treatment Options in Oncology</i> , 2017, 18, 39.	3.0	9
88	Prevalence, prognosis, and treatment implications of retropharyngeal nodes in unknown primary head and neck carcinoma. <i>Oral Oncology</i> , 2018, 82, 162-167.	1.5	9
89	Pre- and Post-Radiotherapy Radiologic Nodal Features and Oropharyngeal Cancer Outcomes. <i>Laryngoscope</i> , 2021, 131, E1162-E1171.	2.0	9
90	Validation of distant metastases risk-groups in oral cavity squamous cell carcinoma patients treated with postoperative intensity-modulated radiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 134, 10-16.	0.6	8

#	ARTICLE	IF	CITATIONS
91	Multiple imputation and clinico-serological models to predict human papillomavirus status in oropharyngeal carcinoma: An alternative when tissue is unavailable. <i>International Journal of Cancer</i> , 2020, 146, 2166-2174.	5.1	8
92	Impact of cumulative cisplatin dose and adjuvant chemotherapy in locally-advanced nasopharyngeal carcinoma treated with definitive chemoradiotherapy. <i>Oral Oncology</i> , 2020, 105, 104666.	1.5	8
93	Treatment outcomes and survival following definitive (chemo)radiotherapy in HPV-positive oropharynx cancer: Large-scale comparison of DAHANCA vs PMH cohorts. <i>International Journal of Cancer</i> , 2022, 150, 1329-1340.	5.1	8
94	Finding/identifying primaries with neck disease (FIND) clinical trial protocol: a study integrating transoral robotic surgery, histopathological localisation and tailored deintensification of radiotherapy for unknown primary and small oropharyngeal head and neck squamous cell carcinoma. <i>BMJ Open</i> , 2019, 9, e035431.	1.9	7
95	Integration of intra-sample contextual error modeling for improved detection of somatic mutations from deep sequencing. <i>Science Advances</i> , 2020, 6, .	10.3	6
96	Automated detection of dental artifacts for large-scale radiomic analysis in radiation oncology. <i>Physics and Imaging in Radiation Oncology</i> , 2021, 18, 41-47.	2.9	6
97	Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib. <i>Clinical Lung Cancer</i> , 2020, 21, e488-e492.	2.6	5
98	Comparing unilateral vs. bilateral neck management in lateralized oropharyngeal cancer between surgical and radiation oncologists: An international practice pattern survey. <i>Oral Oncology</i> , 2021, 114, 105165.	1.5	5
99	Association between Genetic Variants and Cisplatin-Induced Nephrotoxicity: A Genome-Wide Approach and Validation Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 1233.	2.5	5
100	Sexual satisfaction in nasopharyngeal carcinoma survivors: Rates and determinants. <i>Oral Oncology</i> , 2020, 109, 104865.	1.5	4
101	Head and neck imaging surveillance strategy for HPV-positive oropharyngeal carcinoma following definitive (chemo)radiotherapy. <i>Radiotherapy and Oncology</i> , 2021, 157, 255-262.	0.6	4
102	Outcome and treatment toxicity in east-indian versus white-canadian patients with oral cavity cancer following postoperative (chemo-)radiotherapy delivered under similar multidisciplinary care: A propensity-matched cohort study. <i>Oral Oncology</i> , 2021, 120, 105419.	1.5	4
103	Longitudinal health utility and symptom-toxicity trajectories in patients with head and neck cancers. <i>Cancer</i> , 2022, 128, 497-508.	4.1	4
104	Screening for Nasopharyngeal Cancer in High-Risk Populations: A Small Price to Pay for Early Disease Identification?. <i>Journal of the National Cancer Institute</i> , 2021, 113, 803-804.	6.3	3
105	In Reply to Zoto Mustafayev and Ozyar. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 1307.	0.8	2
106	Treatment outcomes in oropharynx cancer patients who did not complete planned curative radiotherapy. <i>Oral Oncology</i> , 2019, 97, 124-130.	1.5	2
107	Healthcare resource utilization following unilateral versus bilateral radiation therapy for oropharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2021, 156, 95-101.	0.6	2
108	Liquid Biopsy Goes Viral: Next-Generation Sequencing to Enhance HPV Detection. <i>Clinical Cancer Research</i> , 2021, 27, 5158-5160.	7.0	2

#	ARTICLE	IF	CITATIONS
109	Outcomes of Oral Cavity Cancer Patients Treated with Definitive Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 99, E330-E331.	0.8	1
110	Human Papillomavirus Genotypes Conferring Poor Prognosis in Head and Neck Squamous Cell Carcinoma—Reply. JAMA Oncology, 2017, 3, 125.	7.1	1
111	Fundamental Biology of Human Papillomaviruses. , 2018, , 1-17.		1
112	Serial Cell-free DNA Assessments in Preclinical Models. STAR Protocols, 2020, 1, 100145.	1.2	1
113	Emerging Precision Oncology Applications of Liquid Biopsy using Circulating Tumour DNA and Methyome Profiling. Clinical Oncology, 2020, 32, 626-631.	1.4	1
114	Short-term and long-term unstimulated saliva flow following unilateral vs bilateral radiotherapy for oropharyngeal carcinoma. Head and Neck, 2021, 43, 456-466.	2.0	1
115	Development and Validation of an Oral Cavity Cancer Outcomes Prediction Score Incorporating Patient-Derived Xenograft Engraftment. JAMA Otolaryngology - Head and Neck Surgery, 2022, , .	2.2	1
116	Potential Impact of the 8th edition UICC/AJCC Staging in Oral Cavity Cancer Patients Treated With Surgery and Post-Operative Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 99, E329-E330.	0.8	0
117	Comparison of the Clinical Behaviour of N3 HPV Related and Unrelated Head and Neck Cancer in the IMRT Era. International Journal of Radiation Oncology Biology Physics, 2018, 102, e346-e347.	0.8	0
118	Clinical Profile and Outcome of Viral-Mediated Pharyngeal Carcinoma at a Western Institution. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1336-1337.	0.8	0
119	Lymph Node Ratio as a Predictor of Distant Metastases in Major Salivary Gland Carcinomas. International Journal of Radiation Oncology Biology Physics, 2018, 102, e274.	0.8	0
120	OC-0277: Development and validation of distant metastases risk group classification in oral cavity cancer. Radiotherapy and Oncology, 2018, 127, S141-S142.	0.6	0
121	PO-0709: Postoperative salvage therapy for early recurrence in oral cavity squamous cell carcinoma. Radiotherapy and Oncology, 2018, 127, S362-S363.	0.6	0
122	PO-0710: Brain dose from IMRT is associated with neurocognitive function in nasopharyngeal cancer survivors. Radiotherapy and Oncology, 2018, 127, S363-S364.	0.6	0
123	PV-0200 Accelerated- vs chemo-radiation as organ sparing strategies for laryngeal/hypopharyngeal carcinoma. Radiotherapy and Oncology, 2019, 133, S103-S104.	0.6	0
124	PO-0733 Non-invasive imaging for tumor hypoxia: a novel validated CT and FDG-PET-based Radiomic signature.. Radiotherapy and Oncology, 2019, 133, S376-S377.	0.6	0
125	EP-1201 Outcomes in young patients (<40) treated for oral cavity squamous cell carcinoma in the modern era. Radiotherapy and Oncology, 2019, 133, S666.	0.6	0
126	The Prevalence and Determinants of Return to Work in Nasopharyngeal Carcinoma Survivors. Journal of Medical Imaging and Radiation Sciences, 2019, 50, S6-S7.	0.3	0



#	ARTICLE	IF	CITATIONS
127	An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells. <i>Journal of Visualized Experiments</i> , 2019, , .	0.3	0
128	Abstract PO-033: The impact of the variation of CT scanner on the prediction of HPV status in head & neck cancer patients. , 2021, , .		0
129	Abstract PO-034: The prediction of mandibular osteoradionecrosis in head and neck cancer patients using CT-derived radiomics features. , 2021, , .		0
130	Abstract 3211: Therapeutic effects of radiotherapy on cancer cell lines using RadioGx computational platform. , 2018, , .		0
131	Abstract 854: Validation of a viability assay for assessing radiation response and investigating drug/radiation combinations. , 2018, , .		0
132	Abstract 583: Rapid release of ctDNA as a biomarker of treatment response in preclinical models of head and neck squamous cell carcinoma. , 2018, , .		0
133	Abstract 1033: Patient-derived xenografts for prognostication and personalized treatment for head and neck squamous cell carcinoma. , 2018, , .		0